Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 15.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 15.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | -- | -- | 15.00M |
| SG&A Expenses | 19.88M | 14.00M | 12.23M | 11.91M | 12.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.77M | 68.47M | 53.79M | 54.65M | 45.78M |
| Operating Income | -79.77M | -68.47M | -53.79M | -54.65M | -30.78M |
| Income Before Tax | -78.39M | -66.69M | -54.73M | -49.57M | -24.74M |
| Income Tax Expenses | 850.00K | -522.00K | 166.00K | 778.00K | 1.40M |
| Earnings from Continuing Operations | -79.24M | -66.16M | -54.89M | -50.34M | -26.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.24M | -66.16M | -54.89M | -50.34M | -26.14M |
| EBIT | -79.77M | -68.47M | -53.79M | -54.65M | -30.78M |
| EBITDA | -79.53M | -68.39M | -53.55M | -54.43M | -30.56M |
| EPS Basic | -0.52 | -0.47 | -0.41 | -0.38 | -0.20 |
| Normalized Basic EPS | -0.32 | -0.29 | -0.25 | -0.23 | -0.12 |
| EPS Diluted | -0.52 | -0.47 | -0.41 | -0.38 | -0.20 |
| Normalized Diluted EPS | -0.32 | -0.29 | -0.25 | -0.23 | -0.12 |
| Average Basic Shares Outstanding | 153.55M | 141.98M | 134.16M | 133.68M | 133.03M |
| Average Diluted Shares Outstanding | 153.55M | 141.98M | 134.16M | 133.68M | 133.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |